Long noncoding RNA myocardial infarction‑associated transcript is associated with the microRNA‑150‑5p/P300 pathway in cardiac hypertrophy

Li,Zhao; Liu,Yamin; Guo,Xiaofan; Sun,Guozhe; Ma,Qun; Dai,Ying; Zhu,Guangshuo; Sun,Yingxian

doi:10.3892/ijmm.2018.3700

Long noncoding RNA myocardial infarction‑associated transcript is associated with the microRNA‑150‑5p/P300 pathway in cardiac hypertrophy

Authors:
- Zhao Li
- Yamin Liu
- Xiaofan Guo
- Guozhe Sun
- Qun Ma
- Ying Dai
- Guangshuo Zhu
- Yingxian Sun
View Affiliations

Affiliations: Department of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Pharmacy, Zhongda Hospital, Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Cardiology, Johns Hopkins University, Baltimore, MD 21205, USA
Published online on: May 21, 2018 https://doi.org/10.3892/ijmm.2018.3700
Pages: 1265-1272
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In numerous diseases, abnormal expression of myocardial infarction‑associated transcript (MIAT) has been reported to be involved in cell proliferation, apoptosis and migration. However, whether this long non‑coding RNA MIAT has a regulatory effect on heart hypertrophy requires further investigation. To this end, the present study evaluated MIAT in hypertrophic cardiomyocytes in vitro and in vivo. Neonatal rat ventricular myocytes (NRVMs) were induced by isoproterenol (ISO) to create a cell hypertrophy model, and mice were intraperitoneally injected with ISO to establish an animal model. Echocardiography, immunofluorescence staining, western blot analysis, RNA isolation and reverse transcription‑polymerase chain reaction were applied to test the involvement of MIAT in cardiac hypertrophy. The results revealed that MIAT was upregulated under ISO stimulation at the mRNA level both in vivo and in vitro. Silencing of MIAT resulted in decreased expression levels of atrial natriuretic peptide and brain natriuretic peptide in ISO‑treated NRVM cardiomyocytes, confirming the connection between MIAT and hypertrophy. Furthermore, MIAT small interfering RNA significantly increased microRNA (miR)‑150 and decreased P300 expression in NRVMs. In conclusion, the MIAT/miR‑150‑5p axis targets P300 as a positive regulator of cardiomyocyte hypertrophy.

View Figures

View References

1	Bertels F, Gokhale CS and Traulsen A: Discovering complete quasispecies in bacterial genomes. Genetics. 206:2149–2157. 2017. View Article : Google Scholar : PubMed/NCBI
2	Wu DD, Irwin DM and Zhang YP: De novo origin of human protein-coding genes. PLoS Genet. 7:e10023792011. View Article : Google Scholar : PubMed/NCBI
3	Zhang D, Xiong M, Xu C, Xiang P and Zhong X: Long noncoding RNAs: An overview. Methods Mol Biol. 1402:287–295. 2016. View Article : Google Scholar : PubMed/NCBI
4	Meller VH, Joshi SS and Deshpande N: Modulation of chromatin by noncoding RNA. Annu Rev Genet. 49:673–695. 2015. View Article : Google Scholar : PubMed/NCBI
5	Tan JY, Vance KW, Varela MA, Sirey T, Watson LM, Curtis HJ, Marinello M, Alves S, Steinkraus BR, Cooper S, et al: Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7. Nat Struct Mol Biol. 21:955–961. 2014. View Article : Google Scholar : PubMed/NCBI
6	Beck ZT, Xing Z and Tran EJ: LncRNAs: Bridging environmental sensing and gene expression. RNA Biol. 13:1189–1196. 2016. View Article : Google Scholar : PubMed/NCBI
7	Ishii N, Ozaki K, Sato H, Mizuno H, Saito S, Takahashi A, Miyamoto Y, Ikegawa S, Kamatani N, Hori M, et al: Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 51:1087–1099. 2006. View Article : Google Scholar : PubMed/NCBI
8	Liao J, He Q, Li M, Chen Y, Liu Y and Wang J: LncRNA MIAT: Myocardial infarction associated and more. Gene. 578:158–161. 2016. View Article : Google Scholar
9	Jiang Q, Shan K, Qun-Wang X, Zhou RM, Yang H, Liu C, Li YJ, Yao J, Li XM, Shen Y, et al: Long non-coding RNA-MIAT promotes neurovascular remodeling in the eye and brain. Oncotarget. 7:49688–49698. 2016. View Article : Google Scholar : PubMed/NCBI
10	Rao SQ, Hu HL, Ye N, Shen Y and Xu Q: Genetic variants in long non-coding RNA MIAT contribute to risk of paranoid schizophrenia in a Chinese Han population. Schizophr Res. 166:125–130. 2015. View Article : Google Scholar : PubMed/NCBI
11	Aprea J, Prenninger S, Dori M, Ghosh T, Monasor LS, Wessendorf E, Zocher S, Massalini S, Alexopoulou D, Lesche M, et al: Transcriptome sequencing during mouse brain development identifies long non-coding RNAs functionally involved in neurogenic commitment. EMBO J. 32:3145–3160. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ishizuka A, Hasegawa Y, Ishida K, Yanaka K and Nakagawa S: Formation of nuclear bodies by the lncRNA Gomafu-associating proteins Celf3 and SF1. Genes Cells. 19:704–721. 2014. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Wang J, Sun L and Zhu S: LncRNA myocardial infarction-associated transcript (MIAT) contributed to cardiac hypertrophy by regulating TLR4 via miR-93. Eur J Pharmacol. 818:508–517. 2018. View Article : Google Scholar
14	Zhu XH, Yuan YX, Rao SL and Wang P: LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci. 20:3653–3660. 2016.PubMed/NCBI
15	Li J, Liu K, Gao X, Yao B, Huo K, Cheng Y, Cheng X, Chen D, Wang B, Sun W, et al: Oxygen- and nitrogen-enriched 3D porous carbon for supercapacitors of high volumetric capacity. ACS Appl Mater Interfaces. 7:24622–24628. 2015. View Article : Google Scholar : PubMed/NCBI
16	Qu Q, Liu Y, Yan X, Fan X, Liu N and Wu G: A Novel pentapeptide targeting integrin β3-subunit inhibits platelet aggregation and its application in rat for thrombosis prevention. Front Pharmacol. 7:492016. View Article : Google Scholar
17	McCommis KS, Douglas DL, Krenz M and Baines CP: Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. J Am Heart Assoc. 2:e0003552013. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Ounzain S, Micheletti R, Beckmann T, Schroen B, Alexanian M, Pezzuto I, Crippa S, Nemir M, Sarre A, Johnson R, et al: Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. Eur Heart J. 36:353a–368a. 2015. View Article : Google Scholar
20	Guo X, Chang Q, Pei H, Sun X, Qian X, Tian C and Lin H: Long non-coding RNA-mRNA correlation analysis reveals the potential role of HOTAIR in pathogenesis of sporadic thoracic aortic aneurysm. Eur J Vasc Endovasc Surg. 54:303–314. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kitow J, Derda AA, Beermann J, Kumarswarmy R, Pfanne A, Fendrich J, Lorenzen JM, Xiao K, Bavendiek U, Bauersachs J and Thum T: Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hyper-trophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 311:H707–H712. 2016. View Article : Google Scholar : PubMed/NCBI
22	Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, Tao ZF, Song YC, Chen Q and Jiang Q: lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 116:1143–1156. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhang J, Chen M, Chen J, Lin S, Cai D, Chen C and Chen Z: Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis. Biosci Rep. 37:BSR201700362017. View Article : Google Scholar :
24	Zhang HY, Zheng FS, Yang W and Lu JB: The long non-coding RNA MIAT regulates zinc finger E-box binding homeobox 1 expression by sponging miR-150 and promoteing cell invasion in non-small-cell lung cancer. Gene. 633:61–65. 2017. View Article : Google Scholar : PubMed/NCBI
25	Otero M, Peng H, Hachem KE, Culley KL, Wondimu EB, Quinn J, Asahara H, Tsuchimochi K, Hashimoto K and Goldring MB: ELF3 modulates type II collagen gene (COL2A1) transcription in chondrocytes by inhibiting SOX9-CBP/p300-driven histone acetyltransferase activity. Connect Tissue Res. 58:15–26. 2017. View Article : Google Scholar :
26	Tikhanovich I, Zhao J, Bridges B, Kumer S, Roberts B and Weinman SA: Arginine methylation regulates c-Myc-dependent transcription by altering promoter recruitment of the acetyltransferase p300. J Biol Chem. 292:13333–13344. 2017. View Article : Google Scholar : PubMed/NCBI
27	Clark MD, Kumar GS, Marcum R, Luo Q, Zhang Y and Radhakrishnan I: Molecular basis for the mechanism of constitutive CBP/p300 coactivator recruitment by CRTC1-MAML2 and Its implications in cAMP signaling. Biochemistry. 54:5439–5446. 2015. View Article : Google Scholar : PubMed/NCBI
28	Naqvi S, Martin KJ and Arthur JS: CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. Biochem J. 458:469–479. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hou T, Ray S, Lee C and Brasier AR: The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. J Biol Chem. 283:30725–30734. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zgheib C, Zouein FA, Chidiac R, Kurdi M and Booz GW: Calyculin A reveals serine/threonine phosphatase protein phosphatase 1 as a regulatory nodal point in canonical signal transducer and activator of transcription 3 signaling of human microvascular endothelial cells. J Interferon Cytokine Res. 32:87–94. 2012. View Article : Google Scholar :
31	Zhou CH, Zhang XP, Liu F and Wang W: Modeling the interplay between the HIF-1 and p53 pathways in hypoxia. Sci Rep. 5:138342015. View Article : Google Scholar : PubMed/NCBI
32	Kato H, Tamamizu-Kato S and Shibasaki F: Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem. 279:41966–41974. 2004. View Article : Google Scholar : PubMed/NCBI
33	Kasper LH, Fukuyama T, Lerach S, Chang Y, Xu W, Wu S, Boyd KL and Brindle PK: Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression. PloS One. 8:e826842013. View Article : Google Scholar : PubMed/NCBI
34	Wang F, Marshall CB, Yamamoto K, Li GY, Gasmi-Seabrook GM, Okada H, Mak TW and Ikura M: Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment. Proc Natl Acad Sci USA. 109:6078–6083. 2012. View Article : Google Scholar : PubMed/NCBI
35	Bedford DC, Kasper LH, Wang R, Chang Y, Green DR and Brindle PK: Disrupting the CH1 domain structure in the acetyltransferases CBP and p300 results in lean mice with increased metabolic control. Cell Metab. 14:219–230. 2011. View Article : Google Scholar : PubMed/NCBI
36	Teufel DP, Freund SM, Bycroft M and Fersht AR: Four domains of p300 each bind tightly to a sequence spanning both trans-activation subdomains of p53. Proc Natl Acad Sci USA. 104:7009–7014. 2007. View Article : Google Scholar
37	Duan Y, Zhou B, Su H, Liu Y and Du C: miR-150-5p regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Exp Cell Res. 319:173–184. 2013. View Article : Google Scholar
38	Prakhar P, Holla S, Ghorpade DS, Gilleron M, Puzo G, Udupa V and Balaji KN: Ac2PIM-responsivmiR-150-5p and miR-143 target receptor-interacting protein kinase 2 and transforming growth factor beta-activated kinase 1 to suppress NOD2-induced immunomodulators. J Biol Chem. 290:26576–26586. 2015. View Article : Google Scholar : PubMed/NCBI